Wuhan YEASEN Biotechnology Co., Ltd.

YEASEN Biotechnology (Shanghai) Co., Ltd. was founded in 2014 and is headquartered in Shanghai International Medical Zone, with offices in Beijing, Tianjin, Nanjing, Hangzhou, Suzhou, Wuhan, Chengdu, Guangzhou, and Shenzhen. It currently has more than 500 employees, including more than 20 PhDs, and master's and doctoral degree holders account for one-third of the workforce. The company focuses on life science tool products, covering molecular diagnostic enzymes, proteins, and antibodies, which are applied in tumor, pathogen, genetic, food safety testing, breeding, judicial, and other industrial fields. It is a high-tech enterprise dedicated to the development of life science tool products.
The company has established four major platforms: molecular, protein, cell, and immunology. It has a comprehensive and rich product line, including PCR, qPCR, high-fidelity DNA polymerase, reverse transcription-related reagents, high-throughput MaxUP series DNA and RNA library preparation kits, cell culture, mycoplasma detection, prevention, and clearance reagents. It also includes in vitro diagnostic-related enzyme raw materials, reagents, and magnetic beads. In 2016, it established a Class 100,000 GMP production facility and automated production lines. In 2017, it was recognized as a high-tech enterprise. The company's Phase II site covers 2,600 square meters. Phase III is expected to reach 8,000 square meters. It has now developed into a first-class domestic enzyme reagent manufacturer.
Wuhan YEASEN Biotechnology Co., Ltd. is a wholly-owned subsidiary of YEASEN Biotechnology (Shanghai) Co., Ltd. The company has a total investment of RMB 200 million and has built a 3,000-square-meter molecular enzyme R&D and GMP-grade production base. It strives to become a benchmark enterprise for the industrialization, R&D, and production of molecular diagnostic reagents and raw materials in line with international standards. The company has four major platforms: Class D cleanroom molecular enzyme fermentation, protein purification, enzyme preparations, and QC quality inspection. It has passed ISO 13485 certification and obtained the ISO 13485:2016 certificate issued by SGS UK and the United Kingdom Accreditation Service (UKAS).
Riding the rapid development trend of life sciences and precision medicine, YEASEN Biotechnology has grown into a high-tech enterprise with nearly 400 people integrating R&D, production, and sales. The company's R&D team is composed of multiple PhDs and has strong R&D strength. With the philosophy of staying true to its original aspiration, contributing modestly to human health, and serving every customer in the life sciences field well, it has united a group of people of insight to strive together. YEASEN Biotechnology sincerely welcomes ambitious individuals to join our YEASEN family.